1. Home
  2. NRIX vs CYD Comparison

NRIX vs CYD Comparison

Compare NRIX & CYD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Nurix Therapeutics Inc.

NRIX

Nurix Therapeutics Inc.

HOLD

Current Price

$15.93

Market Cap

1.7B

Sector

Health Care

ML Signal

HOLD

Logo China Yuchai International Limited

CYD

China Yuchai International Limited

HOLD

Current Price

$44.26

Market Cap

1.7B

Sector

Industrials

ML Signal

HOLD

Company Overview

Basic Information
Metric
NRIX
CYD
Founded
2009
1951
Country
United States
Singapore
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Industrial Machinery/Components
Sector
Health Care
Industrials
Exchange
Nasdaq
Nasdaq
Market Cap
1.7B
1.7B
IPO Year
2020
1998

Fundamental Metrics

Financial Performance
Metric
NRIX
CYD
Price
$15.93
$44.26
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
13
1
Target Price
$29.46
$60.00
AVG Volume (30 Days)
702.7K
247.8K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
1.21%
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$76,987,000.00
N/A
Revenue This Year
N/A
$15.94
Revenue Next Year
$26.32
$7.89
P/E Ratio
N/A
$32.71
Revenue Growth
99.31
N/A
52 Week Low
$8.18
$12.66
52 Week High
$22.50
$56.55

Technical Indicators

Market Signals
Indicator
NRIX
CYD
Relative Strength Index (RSI) 43.58 41.99
Support Level $15.22 $34.58
Resistance Level $16.49 $45.93
Average True Range (ATR) 0.77 3.17
MACD 0.08 -1.29
Stochastic Oscillator 54.86 7.07

Price Performance

Historical Comparison
NRIX
CYD

About NRIX Nurix Therapeutics Inc.

Nurix Therapeutics Inc is a biopharmaceutical company focused on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. The company's pipeline comprises targeted protein degraders of Brutons tyrosine kinase, or BTK, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene-B, or CBL-B, an E3 ligase that regulates T cell activation. Its drug candidate from protein degradation portfolio, NX-2127, is an orally available BTK degrader for the treatment of relapsed or refractory B-cell malignancies.

About CYD China Yuchai International Limited

China Yuchai International Ltd is a Bermuda holding company that is a subsidiary of Singapore-based Hong Leong Asia. China Yuchai International operates through its majority-owned subsidiary Guangxi Yuchai Machinery Company, a China-based company that manufactures, assembles, and distributes diesel engines for various vehicles including trucks, buses, and cars, as well as construction and agricultural, marine, and power-generation equipment. It generates the majority of its sales from the Chinese market.

Share on Social Networks: